The recombinant Cricetulus griseus Peroxiredoxin-1 (PRDX1) is produced by manipulating the expression of specific genes in yeast cells. The gene fragment encoding the Cricetulus griseus PRDX1 protein (2-199aa) is fused to an expression vector along with the N-terminal 6xHis-tag gene and subsequently transformed into yeast cells. The cells that successfully integrate the vector are selected and cultured to induce the expression of the desired protein. The recombinant Cricetulus griseus PRDX1 protein is then purified using affinity purification, achieving a purity level of over 90%, as confirmed by SDS-PAGE analysis.
PRDX1 is a multifunctional protein that acts as a hydrogen peroxide scavenger, a molecular chaperone, and an immune modulator [1]. PRDX1 protects cells from oxidative stress by scavenging oxidants and regulating reactive oxygen species [2][3]. PRDX1 is also involved in different types of cancers, such as breast cancer, colorectal cancer, esophageal cancer, osteosarcoma, head and neck squamous cell carcinoma, and renal cell carcinoma [1][4][2][5][6][7]. In breast cancer, PRDX1 has been identified as a protein biomarker associated with a favorable prognosis [1].
PRDX1 regulates various cellular processes, including cell growth, differentiation, apoptosis, and metastasis [1][8][5][6]. PRDX1 promotes the proliferation and metastasis of cancer cells by enhancing the Akt/mTOR pathway [5]. Additionally, PRDX1 can drive cancer progression by inhibiting ferroptosis and suppressing NRF2 degradation [4]. In esophageal squamous cell carcinoma, PRDX1 causes primary cilia loss, leading to tumor formation [9].
It has been demonstrated that PRDX1 inhibits tumorigenesis by modulating PTEN/AKT signaling pathways [10]. Additionally, PRDX1 has been associated with endothelial activation and early atherosclerosis, suggesting its involvement in vascular health [11].
References:
[1] P. O’Leary, M. Terrile, M. Bajor, P. Gaj, B. Hennessy, G. Millset al., Peroxiredoxin-1 protects estrogen receptor α from oxidative stress-induced suppression and is a protein biomarker of favorable prognosis in breast cancer, Breast Cancer Research, vol. 16, no. 4, 2014. https://doi.org/10.1186/bcr3691
[2] Y. Song, H. Liu, C. Cui, X. Peng, C. Wang, X. Tianet al., <p>silencing of peroxiredoxin 1 inhibits the proliferation of esophageal cancer cells and promotes apoptosis by inhibiting the activity of the pi3k/akt pathway</p>, Cancer Management and Research, vol. Volume 11, p. 10883-10890, 2019. https://doi.org/10.2147/cmar.s235317
[3] J. Robles, Integrated meta-analysis of colorectal cancer public proteomic datasets for biomarker discovery and validation, Plos Computational Biology, vol. 20, no. 1, p. e1011828, 2024. https://doi.org/10.1371/journal.pcbi.1011828
[4] X. Yu, Prdx1 drives colorectal cancer progression by inhibiting ferroptosis through suppression of cullin-3-mediated nrf2 degradation,, 2024. https://doi.org/10.21203/rs.3.rs-4242780/v1
[5] A. Cai, W. Zeng, W. Cai, J. Liu, X. Zheng, Y. Liuet al., Peroxiredoxin-1 promotes cell proliferation and metastasis through enhancing akt/mtor in human osteosarcoma cells, Oncotarget, vol. 9, no. 9, p. 8290-8302, 2017. https://doi.org/10.18632/oncotarget.23662
[6] Y. Jiang, W. Cao, K. Wu, X. Qin, X. Wang, Y. Liet al., Lncrna linc00460 promotes emt in head and neck squamous cell carcinoma by facilitating peroxiredoxin-1 into the nucleus, Journal of Experimental & Clinical Cancer Research, vol. 38, no. 1, 2019. https://doi.org/10.1186/s13046-019-1364-z
[7] X. Zhou, Z. Liang, K. Li, W. Fang, Y. Tian, X. Luoet al., Exploring the natural piericidins as anti-renal cell carcinoma agents targeting peroxiredoxin 1, Journal of Medicinal Chemistry, vol. 62, no. 15, p. 7058-7069, 2019. https://doi.org/10.1021/acs.jmedchem.9b00598
[8] C. Ding, X. Fan, & G. Wu, Peroxiredoxin 1 – an antioxidant enzyme in cancer, Journal of Cellular and Molecular Medicine, vol. 21, no. 1, p. 193-202, 2016. https://doi.org/10.1111/jcmm.12955
[9] Q. Chen, J. Li, X. Yang, J. Ma, F. Gong, & Y. Liu, Prdx1 promotes the loss of primary cilia in esophageal squamous cell carcinoma,, 2020. https://doi.org/10.21203/rs.2.17849/v2
[10] J. Cao, J. Schulte, B. Knight, N. Leslie, A. Zagożdżon, R. Bronsonet al., Prdx1 inhibits tumorigenesis via regulating pten/akt activity, The Embo Journal, vol. 28, no. 10, p. 1505-1517, 2009. https://doi.org/10.1038/emboj.2009.101
[11] J. Kisucka, A. Chauhan, I. Patten, A. Yesilaltay, C. Neumann, R. Ettenet al., Peroxiredoxin1 prevents excessive endothelial activation and early atherosclerosis, Circulation Research, vol. 103, no. 6, p. 598-605, 2008. https://doi.org/10.1161/circresaha.108.174870
